BMS-986141 clinical trials
Also written BMS-986141.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses BMS-986141 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BMS-986141
- 6
Studies by the year they started
7 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BMS-986141 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy ParticipantsCompletedPhase 2Bristol-Myers SquibbNCT05093790Written as BMS-986141
- Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"CompletedPhase 2Bristol-Myers SquibbNCT02671461Written as BMS-986141
- Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy ParticipantsWithdrawnPhase 1Bristol-Myers SquibbNCT03035734Written as BMS-986141 Form A Tablet
- Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02341638Written as BMS-986141
- A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02957448Written as BMS 986141
- A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy ParticipantsWithdrawnPhase 1Bristol-Myers SquibbNCT02985632Written as BMS-986141
- A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02922452Written as BMS-986141